{"name":"Prelude Therapeutics","slug":"prelude-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":12140000,"revenueGrowth":73.4,"grossMargin":0,"rdSpend":94300000,"netIncome":-99498000,"cash":141315000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5qZFhUS0dZM3M1Um9CeXdXLUFkQzlIQ2FVcy10NmpUZ1RmczFmYnJueE9hREUwaVhPSmxrU0F1R3ltZ21mZklxY29WQkZGVmU5c0xHejljNkVqR1VkVmxFS09OcWtPcHlJZEFnbHhR?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Prelude Therapeutics Inc (PRLD) - Stock Titan","headline":"If You Invested $1,000 in Prelude Therapeutics Inc (PRLD)","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFA2Q1FpUGhDZjJhUWRrNDBKdEh5RGF0dzgtcnhaQ0VIVmQ1ci1hSm1pZEdlYW00bnFfSF9GNVRNcng3aXlIMzZWVVlGVWdvdEhvTnoybFZFOWcwLU1PRVZYOWozN0ItaTJwZTZKWk5iOEV1cTlfTDQ4QlE1Vk5Vc03SAYcBQVVfeXFMT214ZzlkQ1U5V1FYOGRnS1hfZklhZE1yT1psQUloMFA4RGM4ZnVnNW50MUd3bW5lOF9xSUlhcV91WGc2WXNHa21SdGhoQVZRcno1ZUVvTmo5YXdXOTVTcVkzVll0UDZ2aEtRQWJvSW5KVjdBclpZdHo4a0NJYmVYRmVxX1A2SVU0?oc=5","date":"2026-02-13","type":"deal","source":"Delaware Business Times","summary":"How Prelude Therapeutics’ deal with Incyte changed its course - Delaware Business Times","headline":"How Prelude Therapeutics’ deal with Incyte changed its course","sentiment":"neutral"},{"date":"2026-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQS0pfMVZIOEh5Zm8zUkVHRFk1dkx6UUtESW5mV2tjbGg4cTA5QlEyTXdISXlZTFAwejVBTnZvaWEyYWpVR2Z3cWFualN5M2lpbl94T1o1d3ZXNmxNTlR4LWs4SDBYVEV0N3djY2dJUnRKNWYwdWZ2QXRjV2cyZU1nNmxZYmhwWm9HOE5UczJlUVFRanJwUkVpdjAxMDdGaXMyT3c?oc=5","date":"2025-11-04","type":"pipeline","source":"Fierce Biotech","summary":"Prelude loses CMO, pauses SMARCA2 degraders and bags $60M from Incyte - Fierce Biotech","headline":"Prelude loses CMO, pauses SMARCA2 degraders and bags $60M from Incyte","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxNb2lZZERIS0UxbFpTMTYwajE5bWpVRFVaVGYtbGR3aGJXZUxlbUx6UWZDMTFXT0N1TWlhNmpzV0tMNjV2eGJyZTlUcFV0VUtFYmZWZkUwZWF5VEFLQWpPWUpodUtxa1k1ZGhmbC1uNk5MV1RVZ2lndHNOTTU0YmphYlVybHpMTGVDWUU3aDVRVXE4bm9qOFJzOG92aDJYUlVfUWtFSUItcHh0bV9BSVhLb1FTR085d3hJd1NXT1JQUk1YeEZnNUxNQzlYdy13TVhOOGQxNDBNY2JBb0xXOGVpLVZhQkg2bFJveFlsVG8wbkxMQ0lDN3gzd2hOQ2lkNWxXcTFuV191M0l1c2pLZFM1Sko4aG1JUXJCUy1qeXQydw?oc=5","date":"2025-11-04","type":"pipeline","source":"GlobeNewswire","summary":"Prelude Therapeutics Announces Exclusive Option Agreement - GlobeNewswire","headline":"Prelude Therapeutics Announces Exclusive Option Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNLUFIZlpaSUVSX19DdGxUa0h0TjFHRHhiM2prVUl1eHQ3MklNckptV1luLU5ncW0zbHcydHpPWEZwUjBkOE5BQ0U0T0tFdWVVb3J0QUs1YXZOZFI0RGp5TzRZV2k5Y2Rrd2g1elRIdUgwVTlmSDc5TG5mY1Y4LURIajhZTW9oTkJoOURlTC1zZw?oc=5","date":"2025-11-04","type":"pipeline","source":"StocksToTrade","summary":"Major Shift in PRLD Stock: What’s Behind the Surge?​ - StocksToTrade","headline":"Major Shift in PRLD Stock: What’s Behind the Surge?​","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOekM4Sl9jSmJNQ3lWYm51R0wxMEt5d015a0pjeGJ1TnVwN0xlWXNkQ0JCQXdlQ3BTQUFSWlFCdUg0Y213ZjhqeFd3THMxUUhSbE9Sc1h3ZURycHBYMnZ1b2FOVTN1a2VFeDY5SDR0ZDR3YWFGWGpURUNtbWI2TXU3VER2Zm9Sd1V0c212WGxEUExtUXNvbUhabnpleUVOR1RWTFpUUlh1OA?oc=5","date":"2025-11-04","type":"pipeline","source":"Stock Titan","summary":"Prelude (NASDAQ: PRLD) signs Incyte option for JAK2V617F; $60M and pipeline refocus - Stock Titan","headline":"Prelude (NASDAQ: PRLD) signs Incyte option for JAK2V617F; $60M and pipeline refocus","sentiment":"neutral"},{"date":"2025-11-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-06-16","type":"pipeline","source":"simplywall.st","summary":"Prelude Therapeutics (NASDAQ:PRLD) Will Have To Spend Its Cash Wisely - simplywall.st","headline":"Prelude Therapeutics (NASDAQ:PRLD) Will Have To Spend Its Cash Wisely","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":12140000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":12140000,"period":"2025-12-31"},{"value":7000000,"period":"2024-12-31"},{"value":7000000,"period":"2024-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":94300000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-99498000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":141315000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}